SEARCH

SEARCH BY CITATION

References

  • 1
    Silverberg E, Lubera J: Cancer statistics, 1986, CA 36: 925, 1986.
  • 2
    Flanders WD: Review: Prostate cancer epidemiology, Prostate 5: 621629, 1984.
  • 3
    Catalona WJ: Epidemiology and etiology, in Catalona WJ: Prostate Cancer. Orlando, Fla, Grune & Stratton, Inc, 1984, pp 114.
  • 4
    Karr JP, Murphy GP: Carcinoma of the prostate and its management, in Brocklehurst JC (ed): Urology in the Elderly. London, Churchill & Livingston, 1984, pp 203230.
  • 5
    Catalona WJ: Pathology, in Catalona WJ: Prostate Cancer. Orlando, Fla, Grune & Stratton, Inc, 1984, pp 1532.
  • 6
    McNeal JE: The prostate gland: Morphology and pathobiology, in Stamey TA (ed): 1983 Monographs in Urology. Custom Pub Services 4: 333, 1983.
  • 7
    Gleason DF, Mellinger GT: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111: 5864, 1974.
  • 8
    Mostofi FK: Problems of grading carcinoma of prostate. Semin Oncol 3: 161169, 1976.
  • 9
    Gaeta JF, Asirwatham JE, Miller G, et al: Histologic grading of primary prostatic cancer: A new approach to an old problem. J Urol 123: 689693, 1980.
  • 10
    Jacobs SC: Spread of prostatic cancer to bone. Urology 21: 337344, 1983.
  • 11
    Spirnak JP, Resnick MI: Clinical staging of prostatic cancer: New modalities. Urol Clin North Am 11: 221235, 1984.
  • 12
    Catalona WJ: Patterns of Dissemination, in Catalona WJ: Prostate Cancer. Orlando, Fla, Grune & Stratton, Inc, 1984, pp 3339.
  • 13
    Schmidt J, Mettlin C, Natarajan N, et al: Trends in the patterns of care and outcomes for prostate cancer in the United States. J Urol (in press).
  • 14
    Pontes JE: Biological markers in prostate cancer. J Urol 130: 10371047, 1983.
  • 15
    Wang MC, Valenzuela LA, Murphy GP, et al: Purification of a human prostate specific antigen. Invest Urol 17: 159163, 1979.
  • 16
    Murphy GP, Karr J, Chu TM: Prostatic acid phosphatase: Where are we? CA 28: 258264, 1978.
  • 17
    Whitmore WF Jr: Natural history and staging of prostate cancer. Urol Clin North Am 11: 205220, 1984.
  • 18
    Fitzpatrick JM, Constable AR, Sherwood T, et al: Serial bone scanning: The assessment of treatment response in carcinoma of the prostate. J Urol 119: 555561, 1978.
  • 19
    Chisholm GD, Stone AR, Beynon LL, et al: The bone scan as a tumour marker in prostatic carcinoma. Eur Urol 8: 257260, 1982.
  • 20
    Pontes JE, Ohe H, Watanabe H, et al: Transrectal ultrasonography of the prostate. Cancer 53: 13691372, 1984.
  • 21
    Whitmore, WF: Hormone therapy in prostatic cancer. Am J Med 21: 697713, 1956.
  • 22
    Jewett HJ: The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am 2: 105124, 1975.
  • 23
    Sonda LP, Grossman HB, MacGregor RJ, et al: Incidental adenocarcinoma of the prostate: The role of repeat transurethral resection in staging. Prostate 5: 141146, 1984.
  • 24
    Parfitt HE Jr, Smith JA Jr, Gliedman JB, et al: Accuracy of staging in A1 carcinoma of the prostate. Cancer 51: 23462350, 1983.
  • 25
    Heaney JA, Chang HC, Daly JJ, et al: Prognosis of clinically undiagnosed prostatic carcinoma and the influence of endocrine therapy. J Urol 118: 283287, 1977.
  • 26
    Gibbons RP, Elder JS, Wheelis RF, et al: Carcinoma of the prostate: Clinical and pathological staging and prognosis. Prostate 4: 441446, 1983.
  • 27
    Catalona WJ, Stein AJ: Staging errors in clinically localized prostatic cancer. J Urol 127: 452456, 1982.
  • 28
    Stamey TA: Cancer of the prostate: An analysis of some important contributions and dilemmas. Monographs in Urology 4: 6892, 1983.
  • 29
    Paulson DF, Piserchia PV, Gardner W: Predictors of lymphatic spread in prostatic adenocarcinoma: Uro-oncology research group study. J Urol 123: 697699, 1980.
  • 30
    Whitmore WF Jr: The natural history of prostatic cancer. Cancer 32: 11041112, 1973.
  • 31
    Elder JS, Catalona WJ: Management of newly diagnosed metastatic carcinoma of the prostate. Urol Clin North Am 11: 283295, 1984.
  • 32
    Donohue RE, Mani JH, Whitesel JA, et al: Stage D1 adenocarcinoma of prostate. Urology 23: 118121, 1984.
  • 33
    Barzell W, Bean MA, Hilaris BS, et al: Prostatic adenocarcinoma: Relationship of grade and local extent to the pattern of metastases. J Urol 118: 278282, 1977.
  • 34
    Murphy GP, Natarajan N, Ponies JE, et al: The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 127: 928934, 1982.
  • 35
    Whitmore WF Jr: Irradiation and/or surgery: Some areas of confrontation in urologic oncology. Am J Clin Oncol 7: 595606, 1984.
  • 36
    Elder JS, Gibbons RP, Correa RJ Jr, et al: Morbidity of radical perineal prostatectomy following transurethral resection of the prostate. J Urol 132: 5557, 1984.
  • 37
    Lytton B, Schiff M Jr, Shonk CR: Treatment of early stage prostatic cancer by implantation of iodine-125 seeds. Surg Clin North Am 605: 12151223, 1980.
  • 38
    Herr HW: The patient, disease status, and treatment options for prostate cancer: Stages B1 and B2. Prostate 4: 447459, 1983.
  • 39
    Pistenma DA, Ray OR, Bagshaw MA: The role of megavoltage radiation therapy in the treatment of prostatic carcinoma. Semin Oncol 3: 115122, 1976.
  • 40
    Whitmore WF Jr, Hilaris B, Grabstald H: Pubic implantation of I-125 in the treatment of prostatic cancer. J Urol 108: 918, 1972.
  • 41
    Paulson DF, Lin GH, Hinshaw W, et al: Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 128: 502504, 1982.
  • 42
    Schmidt JD: Treatment of localized prostatic carcinoma. Urol Clin North Am 11: 305309, 1984.
  • 43
    Walsh PC, Lepor H, Eggleston JC: Radical prostatectomy with preservation of sexual function: Anatomical and pathological considerations. Prostate 4: 473485, 1983.
  • 44
    Freiha FS, Bagshaw MA: Carcinoma of the prostate: Results of post-irradiation biopsy. Prostate 5: 1925, 1984.
  • 45
    Bagshaw MA: External radiation therapy of carcinoma of the prostate. Cancer 45: 19121921, 1980.
  • 46
    Zincke H, Utz DC, Benson RC Jr, et al: Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for stage C adenocarcinoma of prostate. Urology 6: 532539, 1984.
  • 47
    Paulson DF, Hodge GB Jr, Hinshaw W, et al: Radiation therapy versus delayed androgen deprivation for stage C carcinoma of the prostate. J Urol 131: 901902, 1984.
  • 48
    Zincke H, Utz DC, Myers RP, et al: Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for adenocarcinoma of prostate with regional lymph node involvement. Urology 19: 238247, 1982.
  • 49
    Kramer SA, Cline WA Jr. Farnham R, et al: Prognosis of patients with stage D1 prostatic adenocarcinoma. J Urol 125: 817819, 1981.
  • 50
    Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, estrogen and of androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Recent Results Cancer Res 1: 293, 1941.
  • 51
    Murphy GP, Slack NH: The questionable use of hormone therapy in advanced carcinoma of the prostate. Urol Clin North Am 7: 631638, 1980.
  • 52
    Scott WW, Menon M, Walsh PC: Hormonal therapy of prostatic cancer. Cancer 45: 19291936, 1980.
  • 53
    Lepor H, Ross A, Walsh PC: The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 128: 335340, 1982.
  • 54
    Menon M, Walsh PC: Hormonal therapy for prostatic cancer, in Murphy GP (ed): Prostate Cancer. Mass, PSG Pub Co, 1979, pp 175200.
  • 55
    Pollen JJ: Endocrine treatment of prostatic cancer. Urology 21: 555558, 1983.
  • 56
    Resnick MI: Hormonal therapy in prostatic carcinoma. Supp Urology 24: 1823, 1984.
  • 57
    Tolis G, Menta A, Kinch R, et al: Suppression of sex steroids by an LHRH analogue in man. Clin Res 28: 676, 1980.
  • 58
    Trachtenberg J: The effect of the chronic administration of a potent luteinizing hormone releasing hormone analog on the rat prostate. J Urol 128: 10971100, 1982.
  • 59
    Winfield H, Trachtenberg J: A comparison of a powerful luteinizing hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer. J Urol 131: 11071109, 1984.
  • 60
    The Leuprolide Study Group: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311: 12811286, 1984.
  • 61
    Labrie F, Dupont A, Belanger A: New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens. Prostate 4: 579594, 1983.
  • 62
    Sanford FJ, Paulson DF, Rohner TJ Jr, et al: The effects of castration on adrenal testosterone secretion in men with prostatic carcinoma. J Urol 118: 10191021, 1977.
  • 63
    Kerle D, Williams G, Ware H, et al: Experience with an LHRH analogue in the management of relapsed progressive prostatic cancer. Br J Urol 56: 495498, 1984.
  • 64
    Trachtenberg J: Ketoconazole therapy in advanced prostatic cancer. J Urol 132: 6163, 1984.
  • 65
    Torti FM: Prostatic cancer chemotherapy. Recent Results Cancer Res 85: 5869, 1983.
  • 66
    Scott WW, Gibbons RP, Johnson DE, et al: The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate. J Urol 116: 211213, 1976.
  • 67
    Citrin DL, Elson P, DeWys WD: Treatment of metastatic prostate cancer: An analysis of response criteria in patients with measurable soft tissue disease. Cancer 54: 1317, 1984.
  • 68
    Murphy GP, Slack NH: Response criteria for the prostate of the USA National Prostatic Cancer Project, in Murphy GP, Slack NH: The Prostate. New York, Alan R Liss, Inc, 1: 375382, 1980.
  • 69
    Murphy GP, Gibbons RP, Johnson DE, et al: A comparison of estramustine phosphate and streptozotocin in patients with advanced prostatic carcinoma who have had extensive irradiation. J Urol 118: 288291, 1977.
  • 70
    Slack NH: Results of chemotherapy protocols of the USA National Prostatic Cancer Project (NPCP). Clin Oncol 2: 441459, 1983.
  • 71
    Torti FM, Carter SK: The chemotherapy of prostatic adenocarcinoma. Ann Intern Med 92: 681689, 1980.
  • 72
    deKernion JB, Lindner A: Chemotherapy of hormonally unresponsive prostatic carcinoma. Urologic Clinics of North America 11: 319326, 1984.
  • 73
    Murphy GP, Beckley S, Brady MF, et al: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51: 12641272, 1983.
  • 74
    Isaacs JT: The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer, in Murphy GP (ed): The Prostate. New York, Alan R Liss, Inc, 1984, pp 117.
  • 75
    Creaven PJ, Madajewicz S, Mittelman A: New potential treatment modalities for disseminated prostatic cancer. Urol Clin North Am 11: 343356, 1984.
  • 76
    Twycross RG: Analgesics, in Twycross RG (ed): Clinics in Oncology. Philadelphia, Pa, WB Saunders Co, 1984, pp 91108.
  • 77
    McGivney WT, Crooks GM: The care of patients with severe chronic pain in terminal illness. JAMA 251: 11821188, 1984.
  • 78
    Merrin C, Avellanosa A, West C, et al: The value of palliative spinal surgery in metastatic urogenital tumors. J Urol 115: 712713, 1976.
  • 79
    Long DM: Relief of cancer pain by surgical and nerve blocking procedures. JAMA 244: 27592761, 1980.
  • 80
    Twycross RG, Hanks GW: Co-analgesia, in Twycross RG (ed): Clinics in Oncology, Philadelphia, Pa, WB Saunders Co, 1984, pp 153166.